<?xml version="1.0" encoding="UTF-8"?>
<p>Utilisation of FDA-approved drug library is an effective and ideal tool for drug repurposing in antiviral research
 <xref rid="CIT0007" ref-type="bibr">
  <sup>7</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0031" ref-type="bibr">
  <sup>31</sup>
 </xref>, such as zika virus
 <xref rid="CIT0032" ref-type="bibr">
  <sup>32</sup>
 </xref>, human rhinovirus
 <xref rid="CIT0033" ref-type="bibr">
  <sup>33</sup>
 </xref>, and hepatitis B virus
 <xref rid="CIT0034" ref-type="bibr">
  <sup>34</sup>
 </xref>. Regarding the possibility of using FDA-approved drugs for anti-SARS-CoV-2 therapy, we identified twenty potentially active drugs and these are listed in 
 <xref rid="t0001" ref-type="table">Table 1</xref>. Several of those drugs were previously reported to have antiviral activity. For example, ethacrynic acid derivatives have been shown to inhibit SARS-CoV 3CLpro activity by binding directly to the active site
 <xref rid="CIT0035" ref-type="bibr">
  <sup>35</sup>
 </xref>. Naproxen was reported to be incorporated into the RNA-binding groove of the nucleoprotein of influenza A virus, suggesting its potential role in antiviral research
 <xref rid="CIT0036" ref-type="bibr">
  <sup>36</sup>
 </xref>. The therapeutic potential of tranylcypromine for herpes simplex virus 1 (HSV-1) infection was evaluated because of its inhibitory activity against the histone-modifying enzyme, lysine-specific demethylase 1
 <xref rid="CIT0037" ref-type="bibr">
  <sup>37</sup>
 </xref>. Raloxifene, a selective oestrogen receptor modulator, was reported to inhibit Ebola virus infection
 <xref rid="CIT0038" ref-type="bibr">
  <sup>38</sup>
 </xref>. Saquinavir, the first HIV protease inhibitor made available in the market, was shown to be ineffective for inhibiting SARS-CoV replication
 <xref rid="CIT0039" ref-type="bibr">
  <sup>39</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0040" ref-type="bibr">
  <sup>40</sup>
 </xref>. Sirolimus blocked stages after the reverse transcription event in activated human T cells infected by human immunodeficiency virus 1 (HIV-1)
 <xref rid="CIT0041" ref-type="bibr">
  <sup>41</sup>
 </xref>. Cetirizine, an antihistamine reported to inhibit the replication of respiratory syncytial virus (RSV) and the expression of interleukin-8 (IL-8), has an unknown property in reducing of RSV infectivity
 <xref rid="CIT0042" ref-type="bibr">
  <sup>42</sup>
 </xref>. Bexarotene was shown to inhibit the expression of the hepatitis C virus core protein
 <xref rid="CIT0043" ref-type="bibr">
  <sup>43</sup>
 </xref>. As for those that have not been mentioned, they have not yet been evaluated in antiviral research.
</p>
